GlassScriptPhysician profile
Seema Sharma
NPI 1801053541
$4,951.63
in general payments reported to CMS, 2019-2025
45 companies · $965 in 2025
The $965 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $192 · 2021: $793 · 2022: $806 · 2023: $611 · 2024: $913 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $951.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $883.54 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $582.05 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $379.72 | 2019-2025 | |
| Astellas Pharma US INC | $242.67 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $159.15 | 2022-2025 | Breztri, Farxiga |
| Nestle Healthcare Nutrition INC. | $155.76 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.27 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.62 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $144.89 | 2021-2025 | Unithroid |
| Lilly USA, LLC | $135.04 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Amarin Pharma, INC. | $103.38 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $68.50 | 2024-2025 | Keveyis |
| Abbott Laboratories | $59.61 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $44.87 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.